HC Wainwright upgraded Kyverna Therapeutics Inc. KYTX, citing three upcoming data sets through mid-2025. In its first quarter 2025 earnings released, the company highlighted: Enrollment is complete in the registrational Phase 2 KYV-101 trial for stiff person syndrome (SPS). The trial is on track for topline data and a biologics license application (BLA) filing is
BofA Securities analyst Lawson Winder discussed the performance of gold price last week and where it is headed. Gold prices have exceeded the analyst’s long-term target of $3,000 per ounce, with the analyst suggesting a potential rise to $3,500 if investment demand grows by 10%. China’s insurance sector could allocate up to 1% of its
Throughout the last three months, 7 analysts have evaluated Titan Machinery TITN, offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic